Regarding triple-negative breast cancer, EGFR amplification has been reported to occur in approximately 60% of cases when analyzed by silver in situ hybridization, validating this receptor as a target in this malignancy [6]. This evidence concerns the gene EGFR and triple-negative breast carcinoma.